Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion type Assertion NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_head.
- NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_provenance.
- NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion evidence source_evidence_literature NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_provenance.
- NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion SIO_000772 20080466 NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_provenance.
- NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion wasDerivedFrom befree-20140225 NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_provenance.
- NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion wasGeneratedBy ECO_0000203 NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_provenance.